H1 2024 revenue grew 7.63% to ¥6.64B, but net profit fell 20.40% to ¥1.72B due to higher costs and expenses. Biopharma, vaccines, and TCM segments showed mixed results, while real estate rebounded sharply.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.